• Publications
  • Influence
Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy.
Fetal nuchal translucency > or = 3 mm is a useful first trimester marker for fetal chromosomal abnormalities. Expand
Analysis of cell‐free DNA in maternal blood in screening for fetal aneuploidies: updated meta‐analysis
To review clinical validation or implementation studies of maternal blood cell‐free (cf) DNA analysis and define the performance of screening for fetal trisomies 21, 18 and 13 and sex chromosomeExpand
Using fetal nuchal translucency to screen for major congenital cardiac defects at 10-14 weeks of gestation: population based cohort study
Measurement of fetal nuchal translucency thickness—traditionally used to identify fetuses at high risk of aneuploidy—at 10-14 weeks of gestation can identify a large proportion of fetuses with major defects of the heart and great arteries. Expand
Screening for fetal aneuploidies at 11 to 13 weeks
Improvement in the performance of first‐trimester screening can be achieved by firstly, inclusion in the ultrasound examination assessment of the nasal bone and flow in the ductus venosus, hepatic artery and across the tricuspid valve, and secondly, carrying out the biochemical test at 9 to 10 weeks and the ultrasound scan at 12 weeks. Expand
Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities.
  • K. Nicolaides
  • Medicine
  • American journal of obstetrics and gynecology
  • 1 July 2004
There is extensive evidence that effective screening for major chromosomal abnormalities can be provided in the first trimester of pregnancy, and care givers who perform first-trimester screening should be trained appropriately, and their results should be subjected to external quality assurance. Expand
Hypermethylated RASSF1A in maternal plasma: A universal fetal DNA marker that improves the reliability of noninvasive prenatal diagnosis.
Hypermethylated RASSF1A is a universal marker for fetal DNA and is readily detectable in maternal plasma when applied to prenatal RhD genotyping, and allows the detection of false-negative results caused by low fetal DNA concentrations in maternal Plasma. Expand
Evolution of Maternofetal Transport of Immunoglobulins During Human Pregnancy
The evolution of the maternal‐fetal transport of immunoglobulins during human pregnancy is determined and the role of breastfeeding in this evolution is determined. Expand
A screening program for trisomy 21 at 10–14 weeks using fetal nuchal translucency, maternal serum free β‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐A
To examine the potential impact of combining maternal age with fetal nuchal translucency thickness and maternal serum free β‐human chorionic gonadotropin (β‐hCG) and pregnancy‐associated plasmaExpand
Prenatal diagnosis and outcome of echogenic fetal lung lesions
The antenatal findings and outcome of fetuses with echogenic lung lesions are described and the prognosis for these fetuses is described. Expand
First-Trimester Prediction of Hypertensive Disorders in Pregnancy
This study aimed to establish a method of screening for pregnancy hypertension by a combination of maternal variables, including mean arterial pressure, uterine artery pulsatility index, pregnancy-associated plasma protein-A, and placental growth factor in early pregnancy, far superior to the traditional approach, which relies entirely on maternal history. Expand